Evidence map›Paper›PMID 35453214›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Impacts of NaHCO

Selvi C Ersoy, Liana C Chan, Michael R Yeaman, Henry F Chambers, Richard A Proctor, Kevin C Ludwig, Tanja Schneider, Adhar C Manna, Ambrose Cheung, Arnold S Bayer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Genomic investigation and clinical correlates of theAntimicrobial agents and chemotherapy · 2024
    Trial
  2. Review
  3. Phenotypic and genotypic correlates of the sodium bicarbonate-responsive phenotype among methicillin-resistant Staphylococcus aureus isolates from skin and soft-tissue infections.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2025
    Article
  4. Article
  5. Review
  6. Sensitizing methicillin-resistantAntimicrobial agents and chemotherapy · 2024
    Article
  7. Role of the NaHCOMicrobiology spectrum · 2023
    Article
  8. Article
  9. The NaHCOAntimicrobial agents and chemotherapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Selvi C ErsoyThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0002-8792-2061
Liana C ChanThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Michael R YeamanThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Henry F ChambersSchool of Medicine, University of California-San Francisco (UCSF), San Francisco, CA 94143, USA.
Richard A ProctorDepartments of Medicine and Medical Microbiology/Immunology, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53715, USA.
Kevin C LudwigInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, D-53113 Bonn, Germany.ORCID 0000-0003-3534-0729
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, D-53113 Bonn, Germany.
Adhar C MannaDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Ambrose CheungDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Arnold S BayerThe Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0003-1968-0192
University of California, Los Angeles · USDartmouth College · USUniversity of Bonn · DEUCLA Medical Center · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · US

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical TranslatabilityR01AI146078 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
$1.9M
German Center for Infection Research awarded to KCL and TSNCATS NIH HHS KL2 TR001882NIAID NIH HHS R01 AI146078NIH HHS 1R01-AI146078NIH HHS 1U01-AI124319-01University of California, Los Angeles CTSI KL2-TR001882-05
6 · The paper itself

Abstract

Methicillin-resistant

Indexed as

methicillin-resistant Staphylococcus aureuspenicillin-binding proteinssodium bicarbonateβ-lactams

Identifiers

PMID35453214
PMCPMC9028190
OpenAlexW4220890839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.